Moolec Science SA Announces the Implementation of a Share Consolidation of Its Ordinary Shares, Par Value U.S.$0.10 Per Share (the "Shares")
Rhea-AI Summary
Moolec Science (NASDAQ:MLEC) announced a 15-for-1 share consolidation of its ordinary shares, effective at 8:00 a.m. ET on January 5, 2026. The consolidation will change par value from US$0.10 to US$1.50 per share and reduce issued and outstanding shares from 10,891,761 to approximately 726,118. Fractional shares will be rounded up to whole shares; no fractional share certificates will be issued. The consolidated shares will begin trading on Nasdaq Capital Market under CUSIP G6223S125 upon market open on January 5, 2026. The company says the Share Consolidation is intended to regain compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)).
Positive
- Share consolidation ratio set at 15-for-1
- Issued shares reduced to ~726,118
- Consolidation timed to regain Nasdaq minimum $1.00 bid-price compliance
- New par value established at $1.50 per share
Negative
- Share count reduction may reduce share float and liquidity
- Market perception risk if price boost is viewed as cosmetic
News Market Reaction 5 Alerts
On the day this news was published, MLEC declined 4.18%, reflecting a moderate negative market reaction. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $126K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with names like NXTC up 6.72% and PRTG down 10.39%. With no peers in the momentum scanner and conflicting peer moves, MLEC’s reverse split announcement appears stock-specific rather than part of a coordinated biotechnology sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Operational update | Positive | -6.7% | Large-scale GLASO safflower deployment with strong yields and expansion plans. |
| Nov 28 | Listing compliance | Negative | -2.3% | Nasdaq letter over delayed Form 20-F and scheduled hearings on compliance. |
| Nov 21 | Bid-price notice | Negative | -1.6% | Nasdaq notice on sub‑$1.00 bid price and appeal for compliance plan. |
| Sep 11 | Regulatory & corporate | Positive | +11.3% | Argentina approval, U.S. acreage expansion, and appointment of new CFO. |
Recent news tied to Nasdaq listing and compliance concerns generally aligned with negative price reactions, while operational/regulatory wins have seen more positive or mixed responses.
Over the last few months, Moolec has balanced operational milestones with listing and reporting challenges. A Sept 11 update combining Argentine regulatory approval, expanded U.S. acreage, and a new CFO coincided with a 11.29% gain. However, two Nasdaq determination letters in November about minimum bid price and filing delays saw negative reactions of -1.56% and -2.34%. A strong GLASO U.S. campaign update on Dec 11 still led to a -6.67% move. Today’s share consolidation directly addresses the prior bid-price compliance issues highlighted in November.
Market Pulse Summary
This announcement finalizes a 15-for-1 share consolidation, cutting outstanding shares from 10,891,761 to about 726,118 and raising par value to US$1.50. The move targets compliance with Nasdaq’s US$1.00 minimum bid rule following earlier determination letters. Recent history shows a mix of operational progress and listing challenges, so investors may watch whether the consolidation stabilizes trading and how the company advances filings and growth initiatives.
Key Terms
cusip technical
nasdaq capital market financial
minimum bid price financial
AI-generated analysis. Not financial advice.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / December 31, 2025 / Moolec Science SA (NASDAQ:MLEC) "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that its board of directors (the "Board") has determined the effective date and the final ratio for the previously approved share consolidation of Moolec's ordinary shares of par value of US
Accordingly, the number of issued and outstanding ordinary shares will be reduced from 10,891,761 Shares to approximately 726,118 Shares on the Effective Date.
No fractional shares will be issued to any shareholder, and in lieu of issuing any such fractional shares, the fractional shares resulting from the Share Consolidation will be rounded up to the nearest whole share. Except for the adjustments that will result from the treatment of fractional shares, the Share Consolidation will not have any dilutive effect on our shareholders.
Upon the opening of the market on January 5, 2026, the new shares resulting from the Share Consolidation will be admitted to trading on Nasdaq Capital Market under CUSIP number G6223S 125.
The Share Consolidation is intended by the Company to regain compliance with a minimum bid price of U.S.
Continental Stock Transfer & Trust Company, the Company's transfer agent, with its registered office at 1 State Street 30th Floor, New York, NY 10004-1571, is acting as the transfer agent for the Share Consolidation.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward-looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to effect a share consolidation and regain compliance under the NASDAQ rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this report will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Moolec, ir@moolecscience.com (phone: +5493412034927)
SOURCE: Moolec Science
View the original press release on ACCESS Newswire
FAQ
What is the Moolec (MLEC) share consolidation ratio and effective date?
How many Moolec (MLEC) shares will be outstanding after the consolidation?
Will Moolec (MLEC) shareholders receive fractional shares after the consolidation?
Why is Moolec (MLEC) doing the 15-for-1 consolidation?
What will be Moolec (MLEC)'s new par value and CUSIP after consolidation?
Who is handling the mechanics of the Moolec (MLEC) share consolidation?
